Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Nov 2015
Multicenter StudyPhase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
To evaluate safety of TAS-102 administered twice daily (bid) on days 1-5 and 8-12 of a 4-week cycle, confirm feasibility of the Japanese recommended dose (RD), 35 mg/m(2), in Western patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapies, and describe preliminary antitumor activity. ⋯ TAS-102 has an acceptable safety profile and preliminary evidence of disease stabilization in Western patients with refractory mCRC. Results from a randomized phase 3 study have shown survival benefit with disease stabilization evidence in this population.